Osteoarthritis (OA) is an age-related joint degenerative disease associated with pain, joint deformity, and disability. The disease starts with cartilage damage but then progressively involves subchondral bone, causing an imbalance between osteoclast-driven bone resorption and osteoblast-driven remodeling. Here, we summarize the data for the role of oxidative stress and inflammation in OA pathology and discuss how these two processes are integrated during OA progression, as well as their contribution to abnormalities in cartilage/bone metabolism and integrity. At the cellular level, oxidative stress and inflammation are counteracted by transcription factor nuclear factor erythroid p45-related factor 2 (NRF2), and we describe the regulation of NRF2, highlighting its role in OA pathology. We also discuss the beneficial effect of some phytonutrients, including the therapeutic potential of NRF2 activation, in OA.
Introduction
Osteoarthritis (OA) is one of the most common degenerative arthropathies in elderly populations. OA is a time-or age-dependent progressive destruction of joints related to articular cartilage damage, synovial lining thickening, subchondral bone alterations, and osteophyte formation at the joint margin and is supported by elevated inflammatory and catabolic responses, which finally result in a loss of joint architecture and deformity. [1] [2] [3] [4] The disease mostly affects individuals over the age of 50 (primary disease), but it can also develop after joint insult and trauma in younger individuals (posttraumatic OA). Several lines of evidence suggest that aging has an impact on the pathogenesis of primary disease. Some OA chondrocytes acquire an aging phenotype with increased genomic instability; telomere shortening; epigenetic alterations, including decreased genomic global methylation and histone modifications; dysregulated metabolism; mitochondrial dysfunction; and altered intercellular networks and cascades. [5] [6] [7] The disease progresses, and the age-dependent alterations in cell signaling and metabolism occur in chondrocytes but also in bone cells (osteoclasts and osteoblasts), causing an imbalance between bone resorption and remodeling and deeper abnormalities in subchondral bone and joint structure. Aging causes OA development; however, it is not the sole risk factor. The disease is multifactorial, with both physiological and mechanical processes involved, such as obesity, genetic predisposition, heredity, metabolic or endocrine alternations, trauma, joint overload, and mechanical stress, as well as long-time exposure to a low-grade chronic inflammation concomitant with a failure in oxidant-antioxidant balance. [5] [6] [7] [8] Therefore, some aspects of OA pathology remain a subject of extensive research. 4, 9 Inflammation and oxidative stress have been increasingly recognized as being closely integrated in OA pathology. Various inflammatory mediators, such as cytokines (tumor necrosis factor ␣ (TNF-␣) and interleukin (IL)-1␤, -8, -6, -15, -17, -18, -21, and -33), 10 chemokines, prostaglandins (PGEs), 11 and growth factors (transforming growth factor-␣ (TGF-␣) and fibroblast growth factor), are increased in the joint tissue of OA patients in comparison with healthy individuals. 9 Local inflammatory response along with aging and/or mechanical load can contribute to increased oxidative stress with accumulation of reactive oxygen species 12 (ROS), superoxide anion, hydrogen peroxide (H 2 O 2 ), nitric oxide (NO), and peroxynitrite and concomitant failure in the expression of antioxidant enzymes and ROS scavenging systems. 13 At the cellular level, oxidative stress causes mitochondrial DNA (mtDNA) and nuclear DNA damage, lipid peroxidation, alterations in cell signaling and transcription, and epigenetic changes in gene expression. At the level of the joint as a whole organ, oxidative stress causes abnormalities in the cartilage and bone metabolism, exacerbating not only degradation but also overall reparative potential of chondrocytes, osteoblasts, and their precursors. 13, 14 Thus, the regulation of redox homeostasis at the cellular level can decrease the severity of OA and limit disease progression.
The Cap'n'Collar basic leucine zipper (bZIP) transcription factor nuclear factor erythroid 2 p45-related factor 2 (NRF2, also called NFE2L2) is the master regulator of cellular redox homeostasis. NRF2 regulates the expression of a large network of cytoprotective genes, including enzymes involved in the biosynthesis, utilization, and regeneration of reduced glutathione (GSH), thioredoxin, and nicotinamide adenine dinucleotide phosphate (NADPH); detoxification enzymes, such as glutathione S-transferase (GST), aldo-keto reductases, and NAD(P)H:quinone oxidoreductase 1 (NQO1); and heme oxygenase 1 (HO-1), as well as proteins involved in the recognition and clearance of damaged proteins and organelles, such as proteasomal subunits and autophagy-related proteins. 15, 16 Collectively, the products of the NRF2-target genes function to lower the intracellular levels of ROS, reactive nitrogen species (RNS), and electrophiles, thus protecting the cell from the harmful effects of these agents. In addition, NRF2 is involved in the regulation of expression of a number of metabolic genes, most notably those involved in the pentose phosphate pathway, the biosynthesis of purine nucleotides and serine, and enhancing fatty acid metabolism and mitochondrial function. [17] [18] [19] [20] [21] Overall, the NRF2 regulatory network provides an interface between redox and intermediary metabolism.
Recently, several studies have revealed the essential role of NRF2 in preventing pathophysiological events in joint diseases. 22 It has been shown that the appropriate expression and fine balance of NRF2 activity is absolutely necessary for normal chondrogenesis and proper regulation of cartilage metabolism. 12, 23 There is growing evidence for the involvement of NRF2 in bone resorption and remodeling, indicating a multifaceted effect in sustaining overall bone integrity. Here, we attempt to summarize the recent findings for the essential role of NRF2 in OA. We also discuss the underlying mechanisms of regulation and biochemical cross talk among NRF2, ROS signaling, and inflammation during OA pathogenesis. The beneficial role of phytonutrients to attenuate cartilage/bone degradation, inflammation, and oxidative stress in OA is highlighted.
NRF2 function and regulation
NRF2 is expressed in most cell/tissue types and comprises seven functional domains, arranged as follows from its N-to C-terminus: Neh2, Neh4, Neh5, Neh7, Neh6, Neh1, and Neh3 (Fig. 1) . The Neh4 and Neh5 domains form the transactivation domain of the transcription factor that recruits CREB-binding protein (CBP). The retinoid X receptor ␣ (RXR␣) represses NRF2 by binding to its Neh7 domain. Neh1 mediates binding to DNA and to the heterodimeric partner of NRF2, transcription factor of the family of small musculoaponeurotic fibrosarcoma (Maf) proteins. Neh3 recruits the chromo-ATPase/helicase DNA-binding protein 6. The Neh2 and Neh6 domains contain specific sequences (degrons) that mediate the degradation of NRF2.
24 NRF2 is regulated primarily at the level of protein stability. At homeostatic conditions, the levels of NRF2 are low owing to its continuous ubiquitination and proteasomal degradation. In response to stress signals, NRF2 accumulates, translocates to the nucleus, and, as a heterodimer with a small Maf, initiates transcription of its target genes. There are three known ubiquitin ligase systems, which have been implicated in the degradation of NRF2 (Fig. 2) . The major negative regulator of NRF2 activity is Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 was identified as a result of studies that followed the finding that deletion of the Neh2 domain of NRF2 (to which KEAP1 binds) resulted in greatly increased activity. 25 Subsequent research has elucidated the process by which KEAP1 downregulates NRF2 activity. KEAP1 forms a homodimer via its BTB domain. [26] [27] [28] The regions of KEAP1 important for interacting with NRF2 are its Kelch (also known as double glycine repeat) domains and C-terminal regions, and each KEAP1 molecule interacts with one of two proximal portions of NRF2, the DLG and ETGE motifs (Fig. 1) . 29 Both of these motifs lie within the Neh2 domain of NRF2, separated by an ␣ helix, and, owing to their different electrostatic potentials, the ETGE motif has an approximately 100-fold higher affinity for KEAP1 than the DLG motif. 30 A hinge and latch hypothesis has been proposed wherein the lowaffinity site (latch) serves to position NRF2 such that its lysine residues are optimally oriented for ubiquitination, while the high-affinity site (hinge) is primarily responsible for keeping NRF2 bound to KEAP1. 31 KEAP1 uses a cyclic mechanism to sequentially bind to the ETGE and the DLG motifs of NRF2. 32 While bound to both of these sites of KEAP1, NRF2 is in a prime position for ubiquitination by cullin-3 (CUL3)-RBX1/ROC1 ubiquitin ligase (i.e., CRL KEAP1 ), which is recruited to the complex via interactions with the BTB domains of the KEAP1 dimer. 28 Ubiquitinated NRF2 is extracted from the KEAP-CUL3 E3 complex by the ATPdependent segregase p97 33 and degraded by the 26S proteasome-this regulation maintains the half-life of NRF2 at 10-20 min and ensures low basal NRF2 activity. 29 Besides acting as the primary inhibitor of NRF2 activity, KEAP1 serves as the intracellular sensor for electrophiles and oxidants, 27 which induce stabilization and activation of NRF2. This is mediated through specific reactive cysteine residues of KEAP1, some of which have lower pKa values than most cysteine residues owing to their surrounding basic amino acids, meaning they exist as thiolate anions (S -, as opposed to SH), making them more reactive with ROS, RNS, and electrophiles. Which cysteine residues are modified depends on the type of activator, 34 with C151, C273, and C288 being most commonly modified. [35] [36] [37] Small molecule electrophiles and oxidants chemically modify KEAP1 cysteine residues, which is hypothesized to alter the structure of the complex, preventing ubiquitination and subsequent degradation of the transcription factor. This results in KEAP1 becoming saturated with NRF2 and allowing newly synthesized NRF2 to accumulate in the cytoplasm, translocate to the nucleus, and induce expression of its target genes. 32 Alternatively, some toxic metals (As 3+ , Cd 2+ , and Cr 6+ ) have been found to stabilize NRF2 by dissociating it from KEAP1. 38 Other small molecule NRF2 activators directly disrupt the KEAP1-NRF2 protein-protein interaction. 39, 40 Upon translocation to the nucleus, NRF2 forms heterodimers with a small Maf protein, and this dimerization is necessary for efficient DNA binding.
41 NRF2-Maf heterodimers bind their target gene promoters at antioxidant response elements (AREs), which comprise the core sequence 5 -TGACnnnGC-3 , in which the GC dinucleotide is a critical part. 42 Each of these transcription factors contain a bZIP motif found within its DNA-binding domain, with the basic region contributing to DNA binding and the leucine zipper facilitating dimerization. 38 As mentioned above, the Neh4, Neh5, and Neh3 domains of NRF2 (Fig. 1 ) are responsible for mediating transactivation of target genes by recruiting a number of coactivators, whereas the small Maf has no transactivation domain and does not contribute to this process. 43 Coactivators recruited include CBP, coactivatorassociated arginine methyltransferase 1, and protein arginine methyl-transferase 1, which appear to synergize with another recruited coactivator, receptor associated coactivator 3, to facilitate NRF2-mediated gene expression. 44 Other studies have unveiled more bZIP binding partners with which NRF2 dimerizes, including activating transcription factor 4, Fos, and Jun. 45 While these heterodimers have been shown to bind to the ARE, it has not yet been made clear the extent to which they participate in regulating gene expression. Additionally, NRF2 transactivation is subjected to negative regulation by RXR␣, which binds NRF2 and sits at the ARE to prevent binding of NRF2-Maf heterodimers. 46 A recent study has shown that NRF2 binds to MED16, 47 a tail subunit of Mediator, a highly conserved large conformationally flexible macromolecular complex, which is required for RNA polymerase II-driven transcription of all protein-coding genes. 48, 49 Pull-down assays have indicated that the Neh4/Neh5 and the Neh1 domains of NRF2 are involved in this interaction. 47 In addition to KEAP1, NRF2 is targeted for degradation following glycogen synthase kinase 3 ␤ (GSK-3␤)-mediated phosphorylation (Fig. 2) . 50, 51 This kinase phosphorylates serine residues in the Neh6 domain of NRF2, leading to the recruitment, through DSGIS and DSAPGS motifs (Fig. 1) , of the dimeric ␤-transducin repeat-containing protein (␤-TrCP), a substrate adaptor for the SKP1-CUL1-RBX1/ROC1 E3 ligase complex (i.e., SCF ␤-TrCP ), resulting in the degradation of the transcription factor. Activation of certain kinase cascades, including the phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways, leads to inhibition of GSK-3␤, and certain NRF2 activators, such as the lignan nordihydroguaiaretic acid, have been shown to activate NRF2 via induction of these pathways and GSK-3␤ inhibition. 52 A third ubiquitin ligase system, the endoplasmic reticulum (ER)-bound E3 ligase HRD1 (also known as synoviolin), has been implicated in the degradation of NRF2 during ER stress (Fig. 2) . 53 Acetylation also plays a role in NRF2 regulation-the histone acetyl transferases p300 and CBP modify lysine residues of NRF2 within its Neh1 domain to promote its DNA-binding capacity at certain target genes. 54 The activity of NRF2 can be affected by transcriptional and epigenetic mechanisms. Thus, NRF2 transcription is upregulated by the arylhydrocarbon receptor and BRCA1, [55] [56] [57] whereas it is downregulated in the livers of peroxisome proliferator-activated receptor ␣ gene null mice following a 24-h period of fasting. 58 In addition, NRF2 is upregulated in tumor cells with mutant K-Ras G12D or B-Raf V619E , and it has been proposed that this upregulation is mediated by transcription factors Jun and Myc.
59 NRF2 can also activate its own transcription owing to the presence of an ARE-like sequence (5 -CTGACTCCGCC-3 ) in its promoter. 60 The promoter of the murine NRF2 gene (Nrf2) contains five CpG sequences, which have been shown to be hypermethylated in a mouse model of prostate cancer, resulting in a transcriptional silencing of NRF2 and lower target gene expression. 61 Accumulating experimental data suggest that micro-RNAs (miRs) also play a role in the regulation of NRF2. In human MCF-7 breast cancer cells, ectopic expression of miR-28 leads to a decrease in the mRNA and protein levels of NRF2. 62 Overexpression of miR-93 has also been shown to reduce the levels of NRF2 (mRNA and protein) as well as its downstream target NQO1 in human MCF-10A and T47D breast cancer cells. 63 Conversely, the downregulation of miR-93 increased the expression of NRF2 and its target expressing gene HO-1 and had a protective effect in a mouse model of stroke. 64 In human SH-SY5Y neuroblastoma cells, ectopic expression of miR27a, miR-142-5p, miR-144, and miR-153 results in a decrease in the mRNA and protein levels of NRF2 and the expression of NQO1. 65 Downregulation of miR-27a increased NRF2 expression and improved cardiac function in a mouse model of LPS-mediated sepsis. 66 Interestingly, in homozygous sickle cell disease (HbSS) reticulocytes, increased levels of miR-144 are inversely associated with the levels of NRF2 and correlate with decreased GSH regeneration and attenuated antioxidant capacity in HbSS erythrocytes. 67 A recent study has shown that miR-144 reverses chemoresistance in hepatocellular carcinoma cell lines by targeting the 3 -untranslated region (3 -UTR) of NRF2 and promoting its mRNA degradation. 68 By a similar mechanism, miR-153 downregulates NRF2, whereas tanshinone IIA, a diterpene quinone from Salva miltiorrhiza, restores this downregulation, leading to the protection of SH-SY5Y cells against 6-hydroxydopamine-induced toxicity.
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Pathogenesis of osteoarthritis
OA is a worldwide problem accounting for 1.1% of global disability-adjusted life years 10 and is the fourth leading cause of disability, 22 accompanied by pain and depression, as well as social impact on the patients' families. 4, 5, 9 Currently available therapies are limited in efficacy because of the complex pathology and attendant side effects. 70 Most therapies only aim to reduce and control OA symptoms and pain, but they fail to provide a cure, and thus total joint replacement is often required in the most severe cases of OA. 10, 22, 70 At the early stages of disease, the changes in chondrocyte function and survival lead to progressive cartilage disintegration and deterioration. In some patients, this process can be accompanied and perpetuated by secondary inflammation and synovitis. 71 Cartilage degeneration accelerates catabolic processes and bone removal by osteoclasts (bone resorption), resulting in bone cysts and sclerotic bone formation. Cartilage and bone loss trigger compensatory repair by osteoblasts with excessive anabolic processes of neocartilage formation at the joint margins and joint edges (osteophytes), periarticular fibrosis, and calcified bone formation in advanced disease. The repair at specific sites of the joints is also a consequence of generalized alteration in the intrinsic capacity of subchondrial bone to repair the cartilage and in the cross talk between immune and bone cells. 8 Despite the fact that OA can be diagnosed quickly using imaging techniques, the disease progresses slowly over years before the first symptoms, and a risk score for the individual's susceptibility to OA can be predicted on the basis of analysis of genetics, age, and environmental factors in combination with molecular and imaging biomarkers. 8 Such prediction can be based on the assumption that the primary disease develops as a continuum. Mutations and errors in gene expression of matrix molecules or factors regulating matrix component synthesis can render chondrocytes hypertrophic and dysfunctional and can cause chondrodysplasia at a relatively early age. 8 Chondrocytes can acquire this altered phenotype progressively, especially when they are situated near weight-bearing regions. Over time (at middle-age; with aging), OA susceptibility can increase because of supplementary mechanical and structural disorders in the joints associated with reduced physical activity and muscle strength, altered bone metabolism, infections, joint injury, inflammation, and unhealthy diet. 8 Finally, agerelated changes in growth factor signaling required for morphogenesis and repair contribute to OA onset in the elderly population. 8 At middle and late onset, different cell types can be involved in the pathology-chondrocytes, synovial fibroblasts, and bone and immune cells-and all of them may potentially show aberrant gene expression and a failure in oxidant-antioxidant balance. With respect to secondary disease, increased susceptibility to develop OA might be related to altered epigenetic modifications of cartilage after injury. Indeed, more than 1000 differentially methylated regions have been detected in human knee articular cartilage upon damage. 72 An additional factor in the secondary disease is chronic inflammation, often related to dysfunction in immune mechanisms and/or immune cell homeostasis. 73 
Role of inflammation and oxidative stress in osteoarthritis
Inflammation and interactions between immune and bone cells in OA One unresolved link in primary OA is the contribution of inflammation to disease initiation and progression. Several studies have shown a significant association between OA severity and the presence of inflammatory synovitis. 71, 74 Besides OA synovial fibroblasts, OA chondrocytes show altered expression of inflammatory genes, genes encoding transcription factors or regulatory genes, and genes associated with the loss of correct cell maturation. 75, 76 Indeed, overexpression and overproduction of proinflammatory cytokines have been clearly shown to be part of OA pathology. [9] [10] [11] In chondrocytes, cytokines activate the PI3K/Akt and NF-B signaling pathways, upregulate matrix metalloproteinase (MMP)/aggrecanase expression, and increase DNA hydroxymethylation via attenuation of ten-eleven translocation 1-3 (TET1-3) enzymes. 77 OA chondrocytes can also produce chemokines, such as IL-8, which drive neutrophil accumulation. 78, 79 Indeed, neutrophils can seriously affect OA pathology. It has been found that blood neutrophils from OA patients with active disease respond to in vitro stimulation with elicited proinflammatory cytokine production and show elevated expression of bone damage-accelerating receptor activator of NF-B (RANKL). 80 Mature neutrophils expressing RANKL are found in synovial fluid of mice with OA, 81 and disease improvement is associated with inhibition of RANKL expression on neutrophils. 82 Neutrophils actually endow a destructive phenotype in blood that is further extended and sustained in arthritic synovium. 83 In turn, they can drive osteoclast differentiation and maturation from precursor cells directly via the RANKL-RANK pathway, or they can manipulate chondrocyte and osteoblast functions indirectly via ROS, cytokines, and growth factor secretion. Neutrophils can cooperate with natural killer (NK) cells to build the local immune response and can induce general changes in NK homing and activation via secreted chemokines 73 that in turn can fail to support normal cartilage and bone repair. It is still unclear if some of the abnormalities in advanced OA are related to age-dependent dysfunction in immune cells and ROS signaling as well as a shift in the expression of myeloid lineage genes and changes in the composition and quality of the tissuerestricted pools of immune cells. 84 Role of oxidative stress in OA pathology During the past decades, tremendous progress has been made in understanding the role of oxidative stress in health and diseases. ROS, including H 2 O 2 , O 2 • − , and •OH, are by-products of normal cellular metabolism. ROS are generated during electron transport chain reactions delivering electrons to molecular oxygen in the mitochondria. The process is restricted by the redox enzyme p66
Shc , which translocates to the mitochondria in response to exogenous signals delivered by growth factor deprivation, oxidative stress, or UV irradiation. 85, 86 Generated H 2 O 2 can diffuse across the outer mitochondrial membrane to the cytosol, where it can modulate the activity of ROS sensors, such as the thiol functional group of the amino acid cysteine in proteins. Subsequently, the oxidative cysteine modifications can modulate cytosolic protein functions, akin to phosphorylation, and can increase mitochondrial permeability and biogenesis. 86 H 2 O 2 also downregulates the activity of the forkhead transcription factor FOXO3, implicated in the expression of mitochondrial antioxidant enzymes that in turn increase both H 2 O 2 scavenging and oxidative stress resistance. 87 ROS generation in mitochondria can often change during aging, resulting in persistent endogenous ROS production at small amounts contributing to aging-related mitochondrial dysfunction, swelling, and apoptosis, together with alterations in chondrocyte senescence and apoptosis. This pathway is considered to play a minor role in total ROS accumulation, but it has a key implication in agingdependent alterations in OA. 14, 22 Significant amounts of ROS are generated via a nonmitochondrial pathway (i.e., NADPH oxidase (NOX) or dual oxidase (DUOX) assemblies found at the discrete regions at the plasma or endosomal membranes). In phagocytic cells, the active oxidase contains the catalytic subunit (gp91 phox ), the regulatory subunits (p22 phox , p47 phox , p40 phox , and p67 phox ), and the small signaling G protein kinase. Later, it was discovered that nonphagocytic cells from various tissues can express one of the seven homologues of the gp91 phox : NOX1-5 and DUOX1 and -2, all containing a conserved domain structure of six transmembrane ␣-helices and an electron transfer center with two hemes forming the electron transport channel through the membrane. 88 The C-terminal domain of the multicomponent oxidase binds to the electron-donating pyridine nucleotide NADPH and to various cofactors, such as flavin adenine dinucleotide or Ca 2+ , in order to generate superoxide. In a subsequent reaction, two molecules of superoxide can generate H 2 O 2 . Similar to the mitochondrial pathway, H 2 O 2 can induce reversible modifications of cysteine-containing proteins like tyrosine phosphatases adjacent to receptors for growth factors, cytokines, and chemokines or like phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (PTEN), responsible for the hydrolysis of the bioactive lipid phosphatidylinositol 3,4,5-trisphosphate. In such a way, the NOX enzymes can regulate the downstream signaling for cell activation, differentiation, proliferation, and apoptosis in healthy cells. H 2 O 2 can diffuse in the cytosol, but NOX complexes are present at the lipid rafts 89 and assemble at focal adhesion regions, 90 restricting H 2 O 2 to specific cellular microdomains and preventing aberrant signaling. Another system for ROS generation involves the constitutively expressed enzyme xanthine oxidoreductase (XOR). XOR is highly expressed in intestine and liver, as well as in synovium, lung, kidney, and brain. XOR activity is versatile and tuneable at multiple levels. 91 At the genetic level, the expression of the enzyme can be regulated by nutritional factors, oxygen tension, steroid hormones, phorbol esters, regenerative and hyperplastic stimuli, and cytokines implicated in inflammation (like IFN-␥ and TNF-␣). 91 The enzyme can exist in two forms-dehydrogenase and xanthine oxidase (XO), as it undergoes irreversible partial proteolytic cleavage or reversible posttranslational modifications via thiol oxidation. 92, 93 During the latter convertible alteration, XOR enzyme is modified from dehydrogenase via an intermediate form to reversible XO. 91 The conversion of XOR to XO has been observed in a variety of hypoxic and ischemic conditions in tissues, including synovium, and has been linked to vascular response to oxidative stress and the regulation of proinflammatory and prothrombotic activities of endothelial cells. 91 The mechanisms include metabolic alterations and the activation of transcriptional factors, including hypoxia-inducible factor-1 (HIF-1) and protein kinases. 94 XOR can catalyze the oxidation of hypoxanthine to xanthine, can act as a NADH oxidase (the XO form) to catalyze the subsequent oxidation of purines to urate, and can catalyze the reduction of nitrates and nitrites, being the rate-limiting enzyme in purine catabolism as well as a constant source of ROS, NO, and peroxynitrite. 92, 93, 95, 96 XOR level in synovial fluid is elevated in OA patients but to a lesser extent in comparison with that in patients with rheumatoid arthritis, 97 and its amount in synovium correlates with the severity of joint injury [97] [98] [99] and inflammasome activation driving OA progression. 100 More than 50% of synovial XOR exists in the oxidase form and is expressed in synovial tissue upon injury. 97, 101 Increased XO activity is also associated with altered adhesion and accumulation of leukocytes in microvasculature and elevated ROS and cytokine production by infiltrating and locally activated monocytes and neutrophils. 91 Several scavenging systems are available in the cells to detoxify ROS: the enzymes superoxide dismutase (SOD), catalase, GSH peroxidase, and GSH reductase.
102 SOD1 is a dimeric cytosolic enzyme that binds copper and zinc (Cu/ZN-SOD), whereas SOD2 is a mitochondrial homotetramer that binds one manganese ion per subunit (Mn-SOD). Both enzymes convert superoxide to H 2 O 2 and diatomic oxygen. Catalase is a tetrameric protein that converts H 2 O 2 to H 2 O and gaseous O 2 . In the cytosol, the GSH peroxidase/GSH reductase system maintains the reducing environment in cells. When ROS production escapes the antioxidant systems and mechanisms, the cells are exposed to oxidative stress and become sensitive to the activation of apoptotic pathways. ROS-mediated damage can be often reversed by repair, replacement, degradation, or sequestration of the damaged macromolecules, but in some cases the stress can be sustained, driving mitochondrial and cell death or mutagenesis. 85, 86 The biological effects of ROS in all cell types are due to hyperperoxidation, protein carbonylation, direct DNA damage, telomere shortening, epigenetic alterations of gene expression and failure in DNA repair, changes in receptor and metabolic pathways, and autophagy. However, the sources of ROS may differ in various cell types and may be dependent on cell-type functional and metabolic state.
Abnormal ROS signaling has been described in OA synovial tissue, fibroblasts, chondrocytes, osteoblasts, and osteoclasts, concomitant with spatiotemporal progression of injury from the articular surface to the subchondral bone. ROS generation can be influenced by underlying chronic inflammation involving immune cells or by generalized alterations in cell-driven repair affecting nuclear reprogramming (Fig. 3) . Indeed, low levels of ROS are important for normal osteoclastogenesis and osteoblastogenesis to sustain bone integrity, whereas high levels of ROS may contribute to mitochondrial dysfunction and alterations in signaling pathways and gene expression that in turn cause chondrocyte apoptosis and senescence, subsequent cartilage degradation, and changes in subchondral bone and processes of bone resorption and remodeling.
ROS signaling and nuclear programing
Recently, several studies have drawn a clear link between ROS signaling and nuclear cell programming. At physiological levels, ROS can alter nuclear reprogramming of somatic cells to pluripotency, restricting cellular and genomic damage during self-renewal or preventing inappropriate differentiation of pluripotent cells. 103, 104 The mechanism can involve the inhibition of NOX family members, which increases genomic stability and/or the activation of innate immunity in a positive feedback cycle of ROS generation. 105 During early reprogramming, antioxidant enzymes are upregulated, and NRF2 expression gradually increases in coordination with changes in mitochondrial biogenesis and bioenergetic functions. 105 A supplementary mechanism to affect pluripotency is the regulation of H 2 O 2 production from superoxide and consequent cysteine oxidation of transcriptional factors or epigenetic modifiers by H 2 O 2 . 106 Such findings encourage researchers to use inducible pluripotent stem cells (or adult stem cells) for the treatment of degenerative diseases like OA, where an alteration of the cartilage and bone tissue-reparative capacity has been described. Experiments with undifferentiated human mesenchymal stem cells (hMSCs) have shown higher levels of glycolytic enzymes, increased rate of glycolysis for energy supply, and ROS signaling. 107 During the differentiation of hMSCs to osteoblast cells, however, the ability to produce ROS is lost because of increased ROS scavenging, upregulation of antioxidant enzymes, and transition from glycolysis to oxidative phosphorylation. 108 The underlying mechanism involves an initial increase in NRF2, NF-B, and AP-1 activity and induction of HIF-␣. 108 
ROS signaling and OA synovial fibroblasts
Increased expression and protein content of the prooxidant enzymes NOX2 and XO have been shown in synovial tissue of patients with knee OA. 109 The level of the enzymes correlates with local expression of prolidase, an imidodipeptidase with a role in the recycling of collagen. 110 Prolidase is regulated at the posttranscriptional level by integrin-dependent signaling delivered from stimulatory (i.e., thrombin) or inhibitory (i.e., echistatin) ␤ 1 -integrin ligands or by NO donors. 110 Indeed, in serum of patients with knee OA, increased oxidant (measured by ROS, total peroxide, and lipid hydroperoxide levels) and decreased antioxidant state (measured by antioxidant capacity, thiol level, and catalase enzyme activity) are related to elevated serum prolidase activity 111 and elevated inflammasome activity in synovium, indicating a link between ROS signaling, inflammation, and cartilage collagen metabolism. 109 OA synovial fibroblasts show higher production of chemokines, IL-1␤, and TNF-␣ and increased expression of thrombin. 112, 113 Thrombin contributes to fibrin deposition, angiogenesis, proliferation, and proinflammatory processes in OA synovium involving the intensive cleavage of osteopontin 114 and the activation of HO-1. 113 The latter enzyme is a stress-inducible rate-limiting enzyme in heme degradation responsible for cytoprotection against oxidative injury and is upregulated via the activation of PKC␦, c-Src, and NRF2. 113 Thrombin secreted by OA fibroblasts can also alter the metabolism of cartilage chondrocytes via HO-1. The mechanism involves increased production of insulin-like growth factor-1, a reduction of insulin-like growth factor binding protein-3, decreased activation of ERK1/2, and elevated activity of MMPs. 115 Alterations in OA synovial fibroblasts have been also related to their increased sensitivity to local NO donors, which directly contribute to elevated ROS production and oxidative stress. 116 Oxidative stress in OA fibroblasts triggers MAPKs phosphorylation, TAK1-mediated NF-B activation, and COX-2/PGE 2 expression, both reversible by antioxidants, such as N-acetylcysteine and hyaluronic acid. 116 The production of local inflammatory mediators and ROS in OA synovium sustains the proliferative ability of OA fibroblasts and alters the regulatory mechanisms of MMPs and cytokine and growth factor expression. For example, IL-1␤ as well as ROS can induce the expression of particular miRNAs, which control NF-B activation, translocation, and acetylation. On the other hand, miRNA expression can be controlled by histone deacetylases (HDACs), enzymes sensitive to ROS signaling. Recent studies have shown that HDAC inhibitors can directly suppress gene expression of iNOS and MMPs in OA fibroblasts. Indirect effects of their administration include the alteration of NF-B activity and translocation, changes in phosphorylation of p38 and ERK, and control of miR-146a expression.
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ROS signaling and OA chondrocytes Articular human normal cartilage is composed of a hydrated extensive extracellular matrix (ECM) in which a small number of cells (2-3% of the total tissue volume) named chondrocytes are embedded. These cells are the only cell type in the normal mature articular cartilage, are metabolically very active, and normally do not divide after adolescence. They maintain homeostasis and a balance of matrix synthesis and degradation and repair damaged cartilage tissue in OA. 10, 119 Cartilage catabolism comprises secretion of proteases, suppression of matrix synthesis, and inhibition of chondrocyte proliferation, while the anabolism is associated with secretion of antagonistic cytokines, synthesis of protease inhibitors, production of ECM, and cell replication. Early changes in the articular surface include fragmentation, fibrillation and gradual thinning of cartilage, and loss of viscosity of the synovial fluid with alterations in the biochemical composition. 10, 119 Articular chondrocytes from OA patients are deteriorated and have irregularly orientated mitochondria. Indeed, chondrocytes near the fibrillated regions show swollen mitochondria with disoriented cristae and nearby glycogen vacuoles, indicative of altered cell metabolism. 120 In culture, OA chondrocytes show increased mitochondrial mass (as a result of increased citrate synthase (CS) activity) but reduced mitochondrial respiratory activity and changes in mitochondrial membrane potential in comparison with normal chondrocytes. 14, 121 The collapse of the mitochondrial membrane potential results in mitochondrial swelling, disruption of outer mitochondrial membrane, and release of proapoptotic factors, such as cytochrome c, apoptosis-inducing factor, and procaspases.
14 A proteomic study demonstrated that enzymes involved in glycolysis significantly decrease in OA chondrocytes, 119 along with a deficiency in mitochondrial SOD, catalase, and GSH scavenging systems; overproduction of ROS, NO, and detrimental peroxynitrite; and reduction of the ATP pool. 119 Several genomic, lipidomic, 122 and high-resolution mass spectrometry analyses 123 have identified enrichment in pathways related to lipid (eicosanoids) metabolism and oxidative stress in OA chondrocytes. It is assumed that excessive cartilage load can trigger abnormalities in ROS release, mitochondrial function, and energy/metabolic state in some predisposed individuals and in some areas of cartilage. In those individuals, altered ROS signaling can be sustained by aging itself, resulting in the senescence secretory phenotype of chondrocytes. This phenotype includes the upregulation of the expression of MMPs and aggrecanases, cytokines, and growth factors and the integration with the PI3K-Akt, p38, ERK, and NF-B signaling linking cell receptors with metabolic pathways. 124 Consequently, more chondrocytes at the superficial zone acquire alterations in total DNA methylation profile, 125 in histone acetylation of anabolic genes (like SOX9), and in particular miRNAs, leading to a failure in regulation of transcription and stability of antioxidant, inflammatory, and metabolic genes. 126 The persistent ROS generation in combination with altered ROS scavenging in cartilage causes progressive mitochondrial damage in most of the chondrocytes, with changes in oxidative phosphorylation, redox signaling, miRNA-regulated mitochondrial biogenesis, 127 and expression of mitochondrial ROS antagonist chaperones. 119 As a result, chondrocyte apoptosis at superficial cartilage areas increases, and chondrocytes in deeper zones become hypertrophic, disrupting normal endochondral ossification and matrix repair. Hypertrophic chondrocytes usually have metabolic and proliferation defects that can be overcome by antioxidant treatment with N-acetylcysteine 128 or the administration of 17␤-estradiol. 129 They also show alteration in HO-1, which is responsible for the degradation of heme to carbon monoxide (CO), free iron, and biliverdin-IX. In mammals, biliverdin-IX is further converted to bilirubin-IX, an endogenous radical scavenger with recognized anti-inflammatory properties. On the other hand, free iron is rapidly sequestered into the iron-storage protein ferritin, leading to additional antioxidant and antiapoptotic effects. CO also has several biological functions, with antiapoptotic and anti-inflammatory properties. 113 Recently, it has been shown that the accumulation of ROS in chondrocytes can lead to mtDNA mutations. Researchers have even identified the specific mtDNA haplogroups J and T that have been associated with variations in the prevalence and progression of cartilage loss in some European populations. [130] [131] [132] [133] In particular, the J haplotype has been linked to lower serum levels of markers of collagen type-II degradation and of MMPs and higher ATP levels in the Spanish population, while the T haplotype correlates with lower disease risk in a small UK cohort.
131-133
ROS signaling and OA osteoclasts and osteoblasts
Osteoclasts drive the processes of bone resorption and bone matrix loss. Osteoclasts are differentiated from bone marrow monocyte precursors. The process is dependent on NF-B signaling driven by RANKL-RANK or is regulated by IL-17, GM-CSF, and/or IFN-␥ . Osteoblasts, stem cells, stromal cells, neutrophils, NK cells, and even CD4 + T cells that migrated into the bone marrow can drive osteoclastogenesis via direct contact. It has been shown that the RANKL-RANK system stimulates ROS generation in osteoclasts. 134 The administration of the antioxidants N-acetylcysteine and GSH attenuates RANKL-mediated Akt and ERK activation and NF-B signaling (via inhibition of IKK activity and IBa phosphorylation), as well as reducing bone-resorbing activity and regulating osteoclast apoptosis. 135 RANKL-mediated ROS production and osteoclast differentiation are abrogated and blocked when bone marrow precursors are depleted of NOX1 by small interfering RNA (siRNA) or by expression of a dominant-negative mutant of RAC1. 134 The same group has shown that the role of ROS signaling for osteoclast differentiation is dependent on activation of JNK. The osteoblasts drive the opposite processes of bone resorption, bone remodeling, and repair. In OA, the balance between activation of osteoclasts and osteoblasts leads to abnormal remodeling and formation of osteophytes. Similarly to osteoclasts and p38 and transcription factor NF-ATc1, 134 RANKL can attenuate NOX2 mRNA expression, but it can upregulate NOX1 and NOX3 transcription during the differentiation of the macrophage linage to osteoclasts. 136 Indeed, siRNA targeting of p67 phox or p22 phox mRNAs in the macrophage linage downregulates ROS generation, suppresses RANKL-induced osteoclastogenesis, and inhibits the expression of osteoclast marker genes (TRAP, cathepsin K, Atp6i, ClC-7, and NF-ATc1). 136 Similar to osteoclasts, osteoblasts are sensitive to ROS signaling during their differentiation from mesenchymal cells. Osteoblastogenesis involves RUNX2-dependent and -independent mechanisms of gene expression and is dependent on growth factor signaling pathways triggered by bone morphogeneic proteins (BMPs), TGF-␤, and the Wnt cascade. Recently, it was shown that BMP-2 induces a rapid generation of ROS and activation of NOX and that NOX4 activation is a key factor for osteoblast differentiation in response to BMP-2. 137 In differentiated OA osteoblasts, however, oxidative stress can have several effects on their functions. The administration of the antioxidant N-acetylcysteine elevates osteocalcin and type I collagen synthesis and decreases alkaline phosphatase activity in OA osteoblasts. The mechanisms involve activation of p38 and JNK1/2, but not ERK1/2 kinases, induction of ATF-2/CREB activation, inhibition of NF-B, and activation of COX-2 gene promoter activity via the CRE site. Consequently, the antioxidant increases COX-2 and PGE 2 levels but decreases TNF-␣-induced IL-6 production.
138
NRF2 and OA pathogenesis
As a master regulator of cellular redox homeostasis, NRF2 induction may play a key role in OA pathophysiology. NRF2 is responsible for the activation of GST, NQO1, 12 and GSH peroxidase activities, 139 thus attenuating early joint pain.
140
NRF2 is a promoter of HO-1 expression 102,141 and prevents 4-hydroxynonenal (HNE)-induced mitochondrial damage, 3 and its deficiency in mice leads to more severe OA development. 141 HO-1 and ␥ -glutamylcysteine ligase act synergistically as phase 2 antioxidants and were found at higher levels owing to NRF2 activation. 142 In addition, NRF2 is involved in the regulation of ROS production by mitochondria and NOX. 143 Studies in NRF2-deficient mice have shown that they are highly susceptible to chemical-induced toxicity and oxidative burden as a result of dysregulation/loss of expression of detoxification, xenobiotic metabolism, and redox genes. 144, 145 However, other genes, including those involved in protein transport, ubiquitination, phosphorylation, cell cycle, growth, and apoptosis, have also been identified as dependent on NRF2. 146 By using ChIP-sequencing and microarray analyses, 645 basal and 654 inducible direct targets of NRF2 were identified and confirmed to be related to stress response and cell proliferation in mouse embryonic fibroblasts. 147 In humans, polymorphisms in the ARE sequences, to which NRF2 binds, have been reported. 148 Concerning inflammatory responses, a recent review discussed the role of NRF2 in the regulation of the expression of HO-1 during hematopoiesis, development, and activation of lymphoid cells and macrophages, as well the interaction between NRF2 and NF-B and the mechanism of NRF2-regulated NLP3 inflammasomal activity. 149 Abnormal ROS signaling in OA synovial fibroblasts by cytokines, thrombin, or stress is associated with increased NRF2 activity. Oxidative stress in cartilage may trigger the activation of NOX4 and mitochondrial dysfunction. However, both factors may be counteracted by increased NRF2 activation in fibroblasts.
150 NRF2 regulates thrombin-induced production of HO-1 in synovial fibroblasts, and, consequently, inhibition of the NRF2-dependent signaling pathway by NRF2-specific siRNA diminishes HO-1 expression. Thrombin increases NRF2 phosphorylation and binding to the ARE element of the HO-1 gene promoter. NRF2 activity is attenuated by inhibitors of the PAR1/PAR-3, PKC-␦, and c-Src pathways, indicating that all of them are involved in thrombin-induced NRF2 activation in human synovial fibroblasts.
113 NRF2 activation antagonizes cytokine-induced NF-B signaling by limiting IB␣ degradation, suggesting that a failure in this reciprocal interaction may also occur in OA synovial fibroblasts, as they overproduce inflammatory cytokines. 149 However, the specific environment in OA cartilage may contribute to a different role for NRF2 in OA fibroblasts in comparison with that in fibroblasts from other tissues. For example, skin fibroblasts from patients with systemic sclerosis show decreased NRF2 activity, along with elevated inflammatory gene expression and fibrosis. In skin fibroblasts, the NRF2 silencing constitutively elevates collagen synthesis and spontaneous myofibroblast differentiation and enhances TGF-␤ responses, 151 showing that NRF2 may be a key cellintrinsic antifibrotic factor sustaining ECM homeostasis in systemic sclerosis. 151 In another study using human periodontal ligament fibroblasts, it was demonstrated that H 2 O 2 -mediated oxidative stress decreases the osteogenic differentiation of fibroblasts via interference with Wnt/␤-catenin signaling and NRF2 expression at protein and mRNA levels.
152
NRF2 plays a major chondroprotective role in the progression of OA; suppresses IL-1␤-induced MMP-1, MMP-3, and MMP-13 expression at both mRNA and protein levels; and induces the expression of phase 2 antioxidant enzymes, such as NQO1 and HO-1, 9,11,141 as well as suppressing PGE 2 and NO production and inhibiting the phosphorylation of NF-ĸB p65 and IBa in human OA.
11
It has been demonstrated that histone deacetylase inhibitors, 141 physical activity, 142 and phytochemicals, such as protandim, 6-gingerol, 3 ascorbic acid (AA), 153 sulforaphane, 154 curcumin, 155 and carotenoids, 156 as well as broccoli 157 and sesame oil are protective in models of OA by activation of NRF2. 139 Downregulation of NRF2 could result in inhibition of chondrogenesis through apoptotic cell death, but on the other hand stable overexpression of NRF2 caused inhibition of chondral differentiation by reduction of the characteristic markers, such as type II collagen (Coll II), type X collagen (Coll X), and osteopontin. This means that appropriate expression and fine balance in NRF2 activity is absolutely necessary for normal chondrogenesis and proper regulation of OA. 12, 23 NRF2 can also indirectly regulate chondrocyte apoptosis and senescence via the expression of glyoxalase I (an enzyme that detoxifies methylglyoxal). 10 This enzyme regulates the levels of the advanced glycation products (AGEs). 10 The levels of AGEs, such as urinary pentosidine, correlate with the degree of cartilage damage and chondrocyte loss. 158, 159 Thus, the overexpression of the receptors of AGEs in OA might suppress NRF2 and glyoxalase I, respectively. 10 NRF2 has been reported to play important roles in the regulation of inflammatory processes. The induced expression of IL-1␤ and TNF-␣ results in higher expression of NO, which inhibits chondrocyte cytoskeletal actin polymerization and ␤1-integrin-dependent signaling, decreased expression of IL-1␤ receptor antagonist and TGF-␤, suppression of chondrocyte collagen and proteoglycan synthesis, activation of MMPs, and suppression of proliferation, as well as promotion of apoptosis. NO suppresses energy metabolism and directly induces calcification of articular cartilage. During apoptosis, mitochondria sequester Ca 2+ in providing energy to the cells. The excessive Ca 2+ concentrations lead to the opening of mitochondrial permeability, which depolarizes the mitochondria and leads to mitochondrial swelling and apoptosis.
14 NRF2 inhibits NF-B activation and the production of inflammatory mediators, such as IL-1␤ and PGE 2 , as well as MMP-1, MMP-3, and MMP-13, which are important risk factors that have the ability to inhibit type II collagen synthesis in the ECM. 11, 154 The mechanisms of this inhibition are just beginning to be understood, but include repression of transcription of proinflammatory genes. 160 Several lines of evidence indicate that NRF2 is an important factor for osteoclast and osteoblast differentiation as well as to sustain normal skeletal and bone metabolism. NRF2-deficient mice have lower bone mass and bone strength. 161 The same authors described that deletion of Nrf2 inhibits the load-driven gene expression of antioxidant enzymes and WNT5a in cultured primary osteoblasts, 161 indicating that NRF2 regulates the overall bone homeostasis. NRF2 is a key factor in the maintenance of bone microarchitecture, as observed in an animal model of postmenopausal osteoporosis.
162
NRF2 deficiency promotes the RANKL-induced activation of p38, c-Jun, and ERK and induces c-Fos and NF-B activation and osteoclastogenesis, likely owing to dysfunction in the production of antioxidant enzymes and GSH. 163 Overexpression of NRF2 enhances the expression of antioxidant enzymes, inhibits osteoclast differentiation, and attenuates LPS-mediated, RANKL-dependent cranial bone destruction in vivo. 164 The same authors showed that, during osteoclastogenesis, the precursor cells lose NRF2, fail to translocate NRF2 into the nucleus because of KEAP1 upregulation, and downregulate cytoprotective enzymes (HO-1, ␥ -glutamylcysteine synthetase, and glucose-6-phosphate dehydrogenase), elevating ROS production. 164 Consistent with this report is a study demonstrating increased oxidative stress in bone marrow-derived cells from ovariectomized NRF2-deficient mice and a higher responsiveness of bone marrow-derived cells to osteoclastogenic stimuli in vitro. 162 Knockout of BTB and CNC homology 1 (BACH1) genes-the competitor of NRF2 in transcriptional regulation-attenuate RANKLmediated osteoclastogenesis. 165 The mechanism involves RANKL-dependent nuclear import of BACH1 and NRF2 nuclear export, which attenuates NRF2-mediated antioxidant enzymes and ROS signaling in osteoclasts. Moreover, the induction of BACH1 nuclear export inhibited bone destruction in vivo. 165 NRF2 mRNA knockdown or gene deletion increases osteoclastic differentiation from bone marrow-derived macrophages via upregulation of transcription factor NFATc1. 166 Interestingly, in this study, NRF2 inhibited osteoblast differentiation and mineralization via suppression of RUNX2, osteocalcin, and osterix. 166 The number of osteoblasts in bone is increased in Nrf2 knockout mice in comparison with wild-type mice, indicating that both osteoclastogenesis and osteoblastogenesis are dependent on NRF2 or at least require its presence. 166 When NRF2-deficient mice are irradiated, the bone loss and RANKL expression markedly increase, but the mineralization of calvarial osteoblasts decreases, suggesting that the loss of NRF2 can activate ROS signaling, altering the sensitivity to radiation-induced bone damage. Importantly, all of these effects are restored by the antioxidant N-acetylcysteine. 167 The role of NRF2 in osteoblast-driven bone formation has been demonstrated in a model of fracture healing. The underlying mechanism is related to elevated expression of vascular endothelial growth factor and diminished production of osteocalcin in NRF2-deficient mice. 168 Together, these studies have shown that NRF2 plays a key role in regulation of the balance between osteoclast-driven bone resorption and osteoblast-driven remodeling (Fig. 4) . However, in NRF2-deficient mice, altered bone metabolism has not been studied with respect to dysfunctional immunity or/and cytokine production, imposing the need for further investigations. It has not been yet considered whether NRF2 has a critical role in maintaining hematopoietic stem cell function, including effects on cell quiescence and self-renewal potential. NRF2 favors the commitment of both myeloid and lymphoid lineages, suggesting that NRF2 plays a general regulatory role in bone marrow niches. 169 Thus, NRF2 may regulate osteoclastogenesis or osteblastogenesis by stabilization of bone marrow niches with progenitors. It has been shown that NRF2-deficient mice have more severe cartilage damage in two models of OA, the destabilization of the medial meniscus and monosodium iodoacetate models. 141 The chondroprotective role of NRF2 in these models was mediated by the use of HDAC inhibitors inhibiting OA-associated proteins MMP1, MMP3, and MMP13 and the proinflammatory cytokines TNF-␣, IL-1␤, and IL-6. That inhibition of HDAC fails to improve the disease in NRF2-deficient mice 141 supports the notion of a more general cell dysfunction that is likely mediated by epigenetic mechanisms.
The manipulation of stem cells via NRF2
The manipulation of stem cells (from different origin; stem cells or adipose-driven) is a new strategy exploiting the key role of NRF2 in cell differentiation, senescence, and apoptosis. It has been shown that the generation of osteoblast cells from stem cells can be achieved by silencing of NRF2 and autophagy. In vivo, bone formation is enhanced by injection of NRF2-knockdown stem cells. 170 Moreover, therapy with adipose-driven stem cells can be improved by promoting endothelial progenitor cell migration and angiogenesis under hypoxia via TLR4-mediated NF-B signaling and antioxidantdriven NRF2 activation. 
Anti-inflammatory drugs in OA therapy
Currently, there is no satisfactory drug for effective OA treatment, and hence OA cannot be totally cured. Moreover, the existing treatment strategies aim only to control the symptoms and reduce pain. 22 Although there are promising candidates, they are limited in efficacy and associated with certain toxicity. 70 The current management of OA includes (1) behavioral interventions (patient education, exercise, and change in life style); (2) simple analgesics, such as acetaminophen (paracetamol); (3) application of nonsteroidal anti-inflammatory drugs (e.g., COX-2 inhibitors); (4) intra-articular injections of corticosteroids, hyaluronic acid, and glucosamine; and (5) total joint replacement in the most severe cases of OA. 22, 70 Bisphosphonates might have symptomatic and structural benefits for patients with OA. Pamidronate disodium was able to completely prevent OA pathology in rabbits through osteoprotegerin receptor activator of NF-B ligand. Aldendronate reduced osteophyte formation and articular cartilage degeneration. 9 HDAC inhibitors have emerged as a potential therapeutic strategy of OA treatment. Their effect is linked with the acetylation of NRF2, which enhances its functions in OA.
141
Effects of plant-derived or synthetic antioxidants on NRF2 expression in osteoarthritis
Plant-derived antioxidants have a great potential to modulate NRF2 expression. For example, curcumin has well-proven antioxidant activity and can protect human chondrocytes from apoptosis and dysfunction by inhibiting AP-1/NF-B signaling and consequent production of IL-1␤ and activation of MMP-3. 172 The inhibitory effect on NF-B signaling by curcumin may be, at least in part, due to the activation of NRF2. Curcumin stimulates HO-1 gene activity by promoting inactivation of the NRF2-KEAP1 complex, leading to increased NRF2 binding to the resident HO-1 AREs. 173 Calycosin, a compound derived from the Chinese medicinal herb Radix Astragali, has similar effects, as it activates HO-1 and NRF2 in synovial fibroblasts from arthritic patients and inhibits proinflammatory factors. 174 The widely applied antioxidant AA was able to reduce apoptosis and loss of viability and markedly decreased H 2 O 2 -mediated senescence of chondrocytes. AA stimulated the expression of collagens and proteoglycans and inhibited chondrocyte differentiation under oxidative stress through decreasing the activity of NRF2, NF-B, AP1, and MMP-3. 153 Sesame oil treatment for 7 days significantly decreased OA-associated joint pain by decreasing IL-6 and increasing CS activity and myosin heavy-chain IIa mRNA expression. Sesame oil decreased muscular lipid peroxidation, activated NRF2, inhibited ROS, and increased GSH production and GSH peroxidase activity. 139 Protandim R (plant-derived science-based formulation) and 6-gingerol preserved chondrocyte viability and mitochondrial metabolism through NRF2 upregulation and subsequent reduction of IL-1␤ and MMP-13. Wogonin, a naturally occurring flavonoid, revealed potent anti-inflammatory and chondroprotective effects through the activation of ROS/ERK/NRF2 signaling pathways in human OA chondrocytes. This molecule completely suppressed the expression and production of inflammatory mediators (IL-6, COX-2, PGE 2 , iNOS, and NO), as well as matrixdegrading proteases, including MMP-13, MMP-3, and MMP-9. 175 It is noteworthy that the dose responses of exposures to some of the phytochemicals discussed above are often nonlinear J-shaped or inverted U-shaped. 176, 177 Dose responses of this type are known as hormetic dose responses and are characterized by a low-dose stimulation and a high-dose inhibition. 178 The initial event is mild stress, which subsequently engages cellular stress-response mechanisms, including those regulated by NRF2. The transcriptional upregulation of NRF2-dependent and other inducible cytoprotective proteins (also known as vitagenes) allows adaptation and survival and enhanced resistance to subsequent challenges, such as those caused by oxidative stress and chronic inflammation. 179 In addition, natural and synthetic compounds can modulate NLRP3 inflammasome activation via NRF2. For example, treatment of mice with lupus nephritis with epigallocatechin-3-gallate or with citral (3,7-dimethyl-2,6-octadienal; a major active compound in the Chinese herbal medicine Litsea cubeba) attenuates NLRP3 inflammasome activation via NRF2 signaling. 180, 181 By a similar mechanism, mangiferin (2-C-␤-d-gluco-pyranosyl-1,3,6,7-tetrahydroxyxanthone) protects mice with sepsis-induced acute kidney injury, 182 biochanin inhibits acute liver injury, 183 and antroquinonol (active compound from Antrodia camphorata) mitigates IgA nephropathy in mice. 184 Several studies have pointed to the cytoprotective potential of NRF2 against glucocorticoid-induced apoptosis of osteoblastic cells. Dexamethasoneinduced ROS production is suppressed by NRF2 activation and antioxidant enzyme expression by indole-3-carbinol, 185 sulforaphane (a naturally occurring isothiocyanate), 186 and icariside II. 187 Notably, sulforaphane, one of the most potent known naturally occurring NRF2 activators, has been shown to suppress proinflammatory responses and protect cultured human chondrocytes against various proinflammatory and proapoptotic stimuli, including shear stress. 188, 189 When included in the diet, sulforaphane (3 M/day) decreased the arthritis score in a mouse model of OA. 154 The cytotoxic effect of methylglyoxal on osteoblastic cells was reversed by glabridin via NRF2 activation, increases in HO-1 and glyoxalase I, and normalization of mitochondrial function. 190 Icariside II, synthetic SC79, and OSU53 can also prevent dexamethasone-induced apoptosis of osteoblasts via Akt activation downstream of NRF2. 187, 191, 192 All of these compounds may have potential to limit osteoblast cell death, which could lead to osteoporosis or osteonecrosis.
Conclusions and future directions
ROS signaling may play a dual role in OA. At low physiological levels, ROS can be important for cartilage and bone integrity by sustaining nuclear programing during chondrogenesis and osteoclast and osteoblast differentiation, probably via NRF2-sequestration mechanisms. Aging, mechanical load, and inflammation can increase ROS production and can trigger oxidative stress with mitochondrial dysfunction, disturbances in cell signaling, and alterations in epigenetic control of gene expression. Consequently, high levels of ROS signaling and altered NRF2 activity can increase chondrocyte apoptosis with cartilage degradation and induce chondrocyte hypertrophy and dysfunction in subchondral bone. Decreased NRF2 activity may be a result of a failure in its homeostatic posttranslational regulation and/or altered epigenetic and transcriptional regulatory mechanisms. Experimental evidence suggests that the role of NRF2 in bone integrity is complex. Low NRF2 activity may sustain bone resorption, favoring osteoclastogenesis at early stages of OA, whereas high NRF2 activity may enhance osteoblastogenesis in advanced disease stages, inducing extensive bone remodeling. Therapeutic approaches to increase NRF2 activity using pharmacological agents may counteract oxidative stress and inflammation in OA, thus effectively limiting cartilage degradation and bone resorption, whereas overall restoration of homeostatic NRF2 activity may be required to normalize imbalanced bone resorption and remodeling.
